Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash to Debt 5.21
CLSN's Cash to Debt is ranked higher than
71% of the 919 Companies
in the Global Biotechnology industry.

( Industry Median: 16.62 vs. CLSN: 5.21 )
CLSN' s 10-Year Cash to Debt Range
Min: 0.45   Max: No Debt
Current: 5.21

Equity to Asset 0.57
CLSN's Equity to Asset is ranked higher than
67% of the 768 Companies
in the Global Biotechnology industry.

( Industry Median: 0.65 vs. CLSN: 0.57 )
CLSN' s 10-Year Equity to Asset Range
Min: -1.05   Max: 0.97
Current: 0.57

-1.05
0.97
F-Score: 3
Z-Score: -2.30
M-Score: 14.85
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating margin (%) -3682.40
CLSN's Operating margin (%) is ranked higher than
52% of the 825 Companies
in the Global Biotechnology industry.

( Industry Median: -65.07 vs. CLSN: -3682.40 )
CLSN' s 10-Year Operating margin (%) Range
Min: -163200   Max: -75.32
Current: -3682.4

-163200
-75.32
Net-margin (%) -4023.60
CLSN's Net-margin (%) is ranked higher than
52% of the 825 Companies
in the Global Biotechnology industry.

( Industry Median: -69.75 vs. CLSN: -4023.60 )
CLSN' s 10-Year Net-margin (%) Range
Min: -151566.67   Max: -67.41
Current: -4023.6

-151566.67
-67.41
ROE (%) -56.02
CLSN's ROE (%) is ranked higher than
63% of the 870 Companies
in the Global Biotechnology industry.

( Industry Median: -28.10 vs. CLSN: -56.02 )
CLSN' s 10-Year ROE (%) Range
Min: -6771.43   Max: 257.55
Current: -56.02

-6771.43
257.55
ROA (%) -36.13
CLSN's ROA (%) is ranked higher than
66% of the 920 Companies
in the Global Biotechnology industry.

( Industry Median: -21.69 vs. CLSN: -36.13 )
CLSN' s 10-Year ROA (%) Range
Min: -727.9   Max: 121.96
Current: -36.13

-727.9
121.96
ROC (Joel Greenblatt) (%) -2092.27
CLSN's ROC (Joel Greenblatt) (%) is ranked higher than
59% of the 909 Companies
in the Global Biotechnology industry.

( Industry Median: -217.20 vs. CLSN: -2092.27 )
CLSN' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -15483.87   Max: -114.68
Current: -2092.27

-15483.87
-114.68
EBITDA Growth (%) -57.50
CLSN's EBITDA Growth (%) is ranked higher than
52% of the 619 Companies
in the Global Biotechnology industry.

( Industry Median: -8.10 vs. CLSN: -57.50 )
CLSN' s 10-Year EBITDA Growth (%) Range
Min: -57.5   Max: 37.2
Current: -57.5

-57.5
37.2
EPS Growth (%) -48.20
CLSN's EPS Growth (%) is ranked higher than
56% of the 649 Companies
in the Global Biotechnology industry.

( Industry Median: -10.20 vs. CLSN: -48.20 )
CLSN' s 10-Year EPS Growth (%) Range
Min: -48.2   Max: 30.5
Current: -48.2

-48.2
30.5
» CLSN's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q3 2013

CLSN Guru Trades in Q3 2013

Chuck Royce 160,000 sh (unchged)
» More
Q4 2013

CLSN Guru Trades in Q4 2013

Jim Simons 48,307 sh (New)
Chuck Royce 35,555 sh (unchged)
» More
Q1 2014

CLSN Guru Trades in Q1 2014

Chuck Royce 233,159 sh (+555.77%)
Jim Simons Sold Out
» More
Q2 2014

CLSN Guru Trades in Q2 2014

Chuck Royce 233,159 sh (unchged)
» More
» Details

Insider Trades

Latest Guru Trades with CLSN

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)



No Insider Trades Found!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 1.30
CLSN's P/B is ranked higher than
95% of the 978 Companies
in the Global Biotechnology industry.

( Industry Median: 5.71 vs. CLSN: 1.30 )
CLSN' s 10-Year P/B Range
Min: 1.25   Max: 35.74
Current: 1.3

1.25
35.74
P/S 97.10
CLSN's P/S is ranked higher than
66% of the 978 Companies
in the Global Biotechnology industry.

( Industry Median: 20.23 vs. CLSN: 97.10 )
CLSN' s 10-Year P/S Range
Min: 1.61   Max: 2210.6
Current: 97.1

1.61
2210.6
EV-to-EBIT -0.22
CLSN's EV-to-EBIT is ranked higher than
60% of the 978 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. CLSN: -0.22 )
CLSN' s 10-Year EV-to-EBIT Range
Min: 0   Max: 0
Current: -0.22

Current Ratio 6.51
CLSN's Current Ratio is ranked higher than
83% of the 917 Companies
in the Global Biotechnology industry.

( Industry Median: 3.97 vs. CLSN: 6.51 )
CLSN' s 10-Year Current Ratio Range
Min: 0.3   Max: 104.65
Current: 6.51

0.3
104.65
Quick Ratio 6.51
CLSN's Quick Ratio is ranked higher than
84% of the 917 Companies
in the Global Biotechnology industry.

( Industry Median: 3.81 vs. CLSN: 6.51 )
CLSN' s 10-Year Quick Ratio Range
Min: 0.3   Max: 104.65
Current: 6.51

0.3
104.65

Valuation & Return

vs
industry
vs
history
Price/Net Cash 3.72
CLSN's Price/Net Cash is ranked higher than
94% of the 978 Companies
in the Global Biotechnology industry.

( Industry Median: 86.53 vs. CLSN: 3.72 )
CLSN' s 10-Year Price/Net Cash Range
Min: 1.51   Max: 396.49
Current: 3.72

1.51
396.49
Price/Net Current Asset Value 3.68
CLSN's Price/Net Current Asset Value is ranked higher than
93% of the 978 Companies
in the Global Biotechnology industry.

( Industry Median: 52.38 vs. CLSN: 3.68 )
CLSN' s 10-Year Price/Net Current Asset Value Range
Min: 1.5   Max: 396.49
Current: 3.68

1.5
396.49
Price/Tangible Book 1.37
CLSN's Price/Tangible Book is ranked higher than
96% of the 978 Companies
in the Global Biotechnology industry.

( Industry Median: 9.10 vs. CLSN: 1.37 )
CLSN' s 10-Year Price/Tangible Book Range
Min: 1.05   Max: 225.28
Current: 1.37

1.05
225.28
Price/Median PS Value 13.54
CLSN's Price/Median PS Value is ranked higher than
65% of the 978 Companies
in the Global Biotechnology industry.

( Industry Median: 1.91 vs. CLSN: 13.54 )
CLSN' s 10-Year Price/Median PS Value Range
Min: 0.32   Max: 380.45
Current: 13.54

0.32
380.45
Forward Rate of Return (Yacktman) -119.54
CLSN's Forward Rate of Return (Yacktman) is ranked higher than
55% of the 759 Companies
in the Global Biotechnology industry.

( Industry Median: -10.76 vs. CLSN: -119.54 )
CLSN' s 10-Year Forward Rate of Return (Yacktman) Range
Min: 0   Max: 0
Current: -119.54

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:CBOB.Germany
Celsion Corporation was founded in 1982 and is a Delaware corporation. It is an innovative oncology drug development company focused on the development of treatments for those suffering with difficult to treat forms of cancer. The Company is working to develop and commercialize more efficient, effective, targeted chemotherapeutic oncology drugs based on its proprietary heat-activated liposomal technology. The promise of this drug technology is to maximize efficacy while minimizing side-effects common to cancer treatments. The Company's product ThermoDox is being evaluated in a Phase III clinical trial for primary liver cancer (the HEAT study), a Phase II clinical trial for colorectal liver metastasis (CRLM) and a Phase II clinical trial for recurrent chest wall breast cancer. ThermoDox is a liposomal encapsulation of doxorubicin, an approved and frequently used oncology drug for the treatment of a wide range of cancers. Localized heat at mild hyperthermia temperatures (greater than 40 degrees Celsius) releases the encapsulated doxorubicin from the liposome enabling high concentrations of doxorubicin to be deposited preferentially in and around the targeted tumor. The Company is engaged in a limited amount of research and development in its own facilities and also sponsor research programs in partnership with various research institutions, including the National Cancer Institute and Duke University. Competition in the discovery and development of new methods for treating and preventing disease is intense. The Company face, and will continue to face, intense competition from pharmaceutical and biotechnology companies, as well as academic and research institutions and government agencies both in the U.S. and abroad. The Company is subject to the periodic inspection of its clinical trials, facilities, procedures and operations and/or the testing of its products by the FDA to determine whether its systems and processes are in compliance with FDA regulations. The Company's research and development activities, pre-clinical tests and clinical trials, and ultimately the manufacturing, marketing and labeling of its products, are all subject to extensive regulation by the FDA and foreign regulatory agencies.
» More Articles for CLSN

Headlines

Articles On GuruFocus.com
Dead Biotech Plays Surge To Life May 07 2013 
Celsion Corp. (CLSN) CEO Michael H Tardugno buys 6,000 Shares Nov 19 2009 
Celsion Corp. (CLSN) CEO Michael H Tardugno buys 5,000 Shares Aug 17 2009 
Celsion Reports Second Quarter 2009 Financial Results and Business Update Aug 05 2009 
Celsion to Hold Second Quarter 2009 Financial Results Jul 31 2009 
Celsion Corp. (CLSN) CEO Michael H Tardugno buys 3,750 Shares Mar 18 2009 
Celsion Corporation to Hold Conference Call to Discuss Its Announced Japan License Agreement for The Dec 16 2008 
Celsion Corporation Announces Exclusive Japan License Agreement with Yakult Honsha for ThermoDox® Dec 15 2008 

More From Other Websites
INVESTOR ALERT: The Law Firm of Levi & Korsinsky, LLP Launches an Investigation into Celsion Corp.... Sep 17 2014
Celsion Announces Highlights from Three Presentations Given at the International Liver Cancer... Sep 08 2014
Celsion Reports Consolidated Duke University and Celsion's DIGNITY Study Clinical Data on... Sep 04 2014
Celsion Announces Enrollment of First Patient in Global Phase III OPTIMA Study of ThermoDox® in... Sep 02 2014
Celsion to Present at the Rodman & Renshaw 16th Annual Healthcare Conference Aug 28 2014
CELSION CORP Files SEC form 8-K/A, Financial Statements and Exhibits Aug 25 2014
CELSION CORP Financials Aug 19 2014
CELSION CORP Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements... Aug 07 2014
Celsion Corporation Reports Second Quarter 2014 Financial Results Aug 07 2014
Q2 2014 Celsion Corp Earnings Release - Before Market Open Aug 07 2014
Celsion Corporation to Hold Second Quarter 2014 Financial Results Jul 31 2014
Celsion Announces Updated Overall Survival Data from HEAT Study of ThermoDox® in Primary Liver... Jul 28 2014
Celsion (CLSN) in Focus: Stock Adds 5.3% in Session Jul 25 2014
Celsion Announces Positive Interim Data Update from its Phase 2 DIGNITY Study in Breast Cancer Jul 24 2014
Celsion's EGEN Acquisition Brings Immunotherapy And RNA Therapeutics To Its Cancer Platform Jul 22 2014
Celsion Corporation Announces $1 Million NIH, NIBIB - Career Development Award Grant for... Jul 21 2014
Celsion Corporation (NASDAQ: CLSN) to Ring The NASDAQ Stock Market Closing Bell Jul 15 2014
Celsion Corporation Announces Commercialization of Reagent Products Jul 15 2014
Celsion Corporation to Ring the NASDAQ Stock Market Closing Bell on July 16, 2014 Jul 14 2014
CELSION CORP Files SEC form 8-K, Change in Directors or Principal Officers, Submission of Matters to... Jun 23 2014

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK